Fibric acids are FDA indicated to treat patients with primary hypercholesterolemia or mixed dyslipidemia
Fenofibrate is FDA approved for the management and treatment of hypertriglyceridemia, primary hypercholesterolemia, or mixed dyslipidemia
K
Note: At least 2 to 3 months of therapy is required to determine efficacy
Fenofibrate is a antihyperlipidemic agent that can reduce mainly triglyceride levels along with reduction in LDL cholesterol by acting on PPAR-alpha receptor It was suggested that PPAR-MDR3-PL may be the main anti-cholestatic mechanism of fenofibrate (Ghonem et al
Hypertriglyceridemia: Oral: Initial: Antara (micronized): 30 to 90 mg once daily; maximum dose: 90 mg/day
The magnitude of lipid changes depends, however, on the patient’s pretreatment
It is generally accepted that bezafibrate is likely an agonist of PPAR-alpha
However, patients with no adequate therapeutic response to dietary measurements will benefit
Mechanism of action of fenofibrate
Multidrug resistance protein 3 (MDR3) from the bile duct membrane side of hepatocytes is the main determinant of phospholipid secretion (Ros et al
Fenofibrate inhibits this pathogenic mechanism in rats by upregulating the PPAR-α–FoxO3a–PGC-1α signal-transduction pathway [108, 109]
Fenofibrate is a derivative of fenofibric acid, clinically proven for its lipid-modifying effects in the treatment of dyslipidaemia
Fenofibrate: The metabolism of Phenobarbital can be decreased when combined with Fenofibrate
Staels B: A review of bile acid sequestrants: potential mechanism(s) for glucose-lowering effects in type 2 diabetes mellitus
While clofibrate was withdrawn in 2002, fenofibrate
The active moiety of fenofibrate is fenofibric acid
Fenofibrate decreases low-density lipoproteins and total cholesterol Fenofibrate primarily acts on high cholesterol levels by modulating lipid metabolism through its mechanism of action
Drug therapy for hypercholesterolemia and dyslipidemia
Colesevelam is an FDA-approved antihyperlipidemic drug